---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-001393"
form_type: "8-K"
ticker: null
cik: "0001602078"
company_name: "Nemaura Medical Inc."
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:28:55.074959+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nemaura Medical receives Nasdaq delisting notices for MVLS and bid price non-compliance

## Summary
- Received notice on Oct 3-4, 2023 for failing to meet $35M MVLS and $1 bid price requirements.
- Grace periods expired Oct 2 (MVLS) and Oct 3 (bid price) without regaining compliance.
- Company intends to request a hearing before Nasdaq Hearings Panel to stay delisting.
- Panel may grant extension until April 1, 2024; no assurance of continued listing.
- Common stock (NMRD) expected to trade on Nasdaq through hearings process.

## SEC filing metadata
- accession: 0001079973-23-001393
- form_type: 8-K
- cik: 0001602078
- company_name: Nemaura Medical Inc.
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1602078/000107997323001393/0001079973-23-001393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1602078/000107997323001393/nmra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-001393
- JSON: https://secwatch.observer/filing/0001079973-23-001393.json
- Plain text: https://secwatch.observer/filing/0001079973-23-001393.txt

## Key facts
- Listing & Compliance Notices
  Nemaura Medical Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: October 3, 2023. On October 3 and 4, 2023, respectively, the Company received written notices from the Nasdaq Staff indicating that the Company had not regained compliance with the MVLS and Bid Price requirements, and that the Company’s common stock would be subject to delisting from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1602078/000107997323001393/0001079973-23-001393-index.htm
- Listing & Compliance Notices
  Nemaura Medical Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: al Market. Accordingly, the Company was granted a grace period that expired on October 2, 2023. In addition, on April 6, 2023, the Company received a written notice that the Company was not in compliance with the $1 bid price (“Bid Price”) requirement for continued listing set forth in Listing Rule 5550(a)(2) and was granted a grace period that expired on October 3, 2023. On October 3 and 4, 2023, respectively, the Company received written notices from the Nasdaq Staff indicating that the Company had not regained compliance with the MVLS and Bid Price requirements, and that the Company’s commo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1602078/000107997323001393/0001079973-23-001393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.